Shared on10 Aug 25Fair value Decreased 27%
Following a sharp downward revision in expected revenue growth and a substantial rise in the forward P/E ratio, analyst sentiment on FibroGen has weakened, leading to a notable decrease in the consensus price target from $58.77 to $43.00. What's in the News FDA provided positive feedback supporting advancement of roxadustat for anemia in LR-MDS patients with high transfusion burden; Phase 3 trial protocol aligns with FDA recommendations and targets 200 patients.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 489%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 62.0x to 69.1x.